ALB and atrial fibrillation: The trial involved 177 individuals who were preselected because they were positive for serum AF-albumin; these participants were randomly assigned to a high dose (3.0 g clay/day), low dose (1.5 g clay/day), or placebo control group, for 3 months [184].